Prescription Transparency Act of 2018

Bill: 115-hr-5343
Sponsor: full_name: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Introduced: 2018-03-20
Policy area: Health
Subjects: Business ethics

Consumer affairs

Contracts and agency

Drug therapy

Health care costs and insurance

Health personnel

Medical ethics

Prescription drugs
Latest action: action_date: 2018-03-23
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2018-03-20
action_desc: Introduced in House
text: <p><strong>Prescription Transparency Act of 2018</strong></p> <p>This bill prohibits contract provisions between a health insurer&nbsp;and a pharmacy that prohibit or penalize a pharmacist's disclosure to an individual purchasing a prescription drug&nbsp;of information regarding&nbsp;(1) the cost of the drug, (2) the availability of any therapeutically equivalent alternative drug,&nbsp;or (3) less expensive methods of purchasing the drug.</p>

tv_txt: I 115th CONGRESS 2d Session H. R. 5343 IN THE HOUSE OF REPRESENTATIVES March 20, 2018 Mr. Carter of Georgia (for himself, Mr. Welch , Mr. Griffith , Mr. Austin Scott of Georgia , Mr. Collins of Georgia , and Mrs. McMorris Rodgers ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to nullify certain contractual provisions prohibiting or penalizing a pharmacist’s disclosure of the availability of therapeutically equivalent alternative drugs, or alternative methods of purchasing the prescription drug, that are less expensive, and for other purposes.

1. Short title This Act may be cited as the Prescription Transparency Act of 2018 . 2. Prohibited gag provisions Part B of title III of the Public Health Service Act ( 42 U.S.C. 243 et seq.) is amended by adding at the end the following: 320B. Prohibited gag provisions (a) In general No contract that is between— (1) a health insurer or any entity that provides pharmacy benefits management services on behalf of a health insurer (commonly referred to as a pharmacy benefit manager ); and (2) a pharmacy, pharmacist, or a pharmacy's contracting agent, such as a pharmacy services administrative organization, may contain a provision prohibiting or penalizing (including through increased utilization review, reduced payments, or other financial disincentives) a pharmacist’s disclosure to an individual purchasing a prescription drug of information regarding the cost of the prescription drug to the individual (including any copayment or coinsurance), or regarding the availability of any therapeutically equivalent alternative drug, or alternative methods of purchasing the prescription drug (including paying a cash price), that are less expensive than the cost of the prescription drug to the individual. (b) Null and void Any provision described in subsection (a) in a contract described in subsection (a) is null and void. (c) Applicability Subsection (a) applies only with respect to contracts, and contract addenda, entered into or renewed on or after the date of enactment of the Prescription Transparency Act of 2018 . (d) Regulations and guidance The Secretary may issue such regulations and guidance as may be necessary for implementation of this section. (e) Definitions In this section: (1) The term drug has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act. (2) The term health insurer means a health insurance issuer (as defined in section 2791) offering health insurance coverage (as defined in such section) in the individual or group market or a sponsor of a group health plan (as defined in such section). (3) The term prescription drug means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act. .